Research programme: anti-angiomotin antibodies - BioInvent

Drug Profile

Research programme: anti-angiomotin antibodies - BioInvent

Alternative Names: Angiomotin monoclonal antibody; Cancer antibodies - BioInvent; n-CoDeR anti Angiomotin

Latest Information Update: 09 Jul 2014

Price : $50

At a glance

  • Originator Karolinska Institute; Servier
  • Developer BioInvent International; Servier
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Jul 2014 Preclinical development is ongoing in Sweden
  • 04 Jan 2012 BioInvent and Servier have entered into an antibody discovery and research agreement in Cancer
  • 30 Sep 2006 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top